Fig. 7: Immune checkpoint expression stratified by PCDI score. | npj Precision Oncology

Fig. 7: Immune checkpoint expression stratified by PCDI score.

From: An AI-driven multi-omics framework identifies lactylation-mediated therapeutic targets to overcome drug resistance in ovarian cancer

Fig. 7: Immune checkpoint expression stratified by PCDI score.The alternative text for this image may have been generated using AI.

Violin plots depicting the expression levels of key immune checkpoint genes (CD274, CTLA4, HAVCR2, TIGIT, LAG3, PDCD1, PDCD1LG2, and SIGLEC15) between PCDI-High (red) and PCDI-Low (blue) groups. Higher expression of all checkpoints was observed in the PCDI-High group, indicating a potentially immunosuppressive tumor microenvironment. Significance levels are denoted as follows: p < 0.001. It also correlated the PCDI score with clinical variables. PCDI-high tumors were more frequently late-stage: patients with advanced stage (IV/III) disease had notably higher PCDI scores than those with the stage I/II. Patients who had died of disease had higher PCDI scores than those alive at last follow-up.

Back to article page